Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: Implications for patient selection

Filippo Montemurro, Gabriela Randón, Mark Munsell, Terry L. Smith, Michele L. Donato, James L. Gajewski, Zia U. Rahman, Aman U. Buzdar, Richard E. Champlin, Naoto T. Ueno

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The aim of this study was to study the effectiveness of the Swenerton score in assessing extent of disease as an independent prognostic and predictive factor in patients with metastatic breast cancer (MBC) who receive high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell transplant (AHSCT). Two-hundred thirty-two patients with MBC underwent HDCT. Extent of disease was assessed quantitatively using the Swenerton score. A retrospective analysis was performed using Cox proportional hazards regression and logistic regression models. One hundred three (44%) patients had a complete response (CR) after HDCT. Bone marrow as source of hematopoietic stem cells, hormone-receptor-negative status, and visceral involvement correlated with both worse overall survival (OS) and progression-free survival (PFS). Short disease-free interval, multiple sites of metastatic disease, and less than 50% reduction in the Swenerton Score during induction chemotherapy correlated with worse OS. Patients in CR at the time of HDCT had better PFS than patients in partial response, stable disease, or progressive disease. Fifty-six patients who underwent conversion to CR after HDCT had a similar median OS (not reached v 74 months; P = .51) and PFS duration (22 v 44 months; P = .15) as patients who received HDCT after a CR to standard-dose chemotherapy (SDCT). Conversion to CR was predicted by a ≥50% reduction in the Swenerton score during SDCT (odds ratio [OR] 3.32, P <.01) and soft-tissue disease (OR 4.08, P <.01). The presence of multiple metastatic sites predicted decreased probability of conversion to CR (OR 0.34, P <.01). The Swenerton score provides a thorough estimate of disease extent, and reduction of Swenerton score by SDCT is potentially useful for selecting the optimal candidates for HDCT trials who may achieve long-term disease control.

Original languageEnglish (US)
Pages (from-to)330-340
Number of pages11
JournalBiology of Blood and Marrow Transplantation
Volume9
Issue number5
DOIs
StatePublished - May 2003
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Patient Selection
Breast Neoplasms
Drug Therapy
Disease-Free Survival
Odds Ratio
Hematopoietic Stem Cells
Survival
Logistic Models
Induction Chemotherapy
Bone Marrow
Hormones
Transplants

Keywords

  • Autologous transplantation
  • Breast neoplasm
  • High-dose chemotherapy

ASJC Scopus subject areas

  • Transplantation

Cite this

Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation : Implications for patient selection. / Montemurro, Filippo; Randón, Gabriela; Munsell, Mark; Smith, Terry L.; Donato, Michele L.; Gajewski, James L.; Rahman, Zia U.; Buzdar, Aman U.; Champlin, Richard E.; Ueno, Naoto T.

In: Biology of Blood and Marrow Transplantation, Vol. 9, No. 5, 05.2003, p. 330-340.

Research output: Contribution to journalArticle

Montemurro, Filippo ; Randón, Gabriela ; Munsell, Mark ; Smith, Terry L. ; Donato, Michele L. ; Gajewski, James L. ; Rahman, Zia U. ; Buzdar, Aman U. ; Champlin, Richard E. ; Ueno, Naoto T. / Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation : Implications for patient selection. In: Biology of Blood and Marrow Transplantation. 2003 ; Vol. 9, No. 5. pp. 330-340.
@article{d89efb436427403296580fb176451b5c,
title = "Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: Implications for patient selection",
abstract = "The aim of this study was to study the effectiveness of the Swenerton score in assessing extent of disease as an independent prognostic and predictive factor in patients with metastatic breast cancer (MBC) who receive high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell transplant (AHSCT). Two-hundred thirty-two patients with MBC underwent HDCT. Extent of disease was assessed quantitatively using the Swenerton score. A retrospective analysis was performed using Cox proportional hazards regression and logistic regression models. One hundred three (44{\%}) patients had a complete response (CR) after HDCT. Bone marrow as source of hematopoietic stem cells, hormone-receptor-negative status, and visceral involvement correlated with both worse overall survival (OS) and progression-free survival (PFS). Short disease-free interval, multiple sites of metastatic disease, and less than 50{\%} reduction in the Swenerton Score during induction chemotherapy correlated with worse OS. Patients in CR at the time of HDCT had better PFS than patients in partial response, stable disease, or progressive disease. Fifty-six patients who underwent conversion to CR after HDCT had a similar median OS (not reached v 74 months; P = .51) and PFS duration (22 v 44 months; P = .15) as patients who received HDCT after a CR to standard-dose chemotherapy (SDCT). Conversion to CR was predicted by a ≥50{\%} reduction in the Swenerton score during SDCT (odds ratio [OR] 3.32, P <.01) and soft-tissue disease (OR 4.08, P <.01). The presence of multiple metastatic sites predicted decreased probability of conversion to CR (OR 0.34, P <.01). The Swenerton score provides a thorough estimate of disease extent, and reduction of Swenerton score by SDCT is potentially useful for selecting the optimal candidates for HDCT trials who may achieve long-term disease control.",
keywords = "Autologous transplantation, Breast neoplasm, High-dose chemotherapy",
author = "Filippo Montemurro and Gabriela Rand{\'o}n and Mark Munsell and Smith, {Terry L.} and Donato, {Michele L.} and Gajewski, {James L.} and Rahman, {Zia U.} and Buzdar, {Aman U.} and Champlin, {Richard E.} and Ueno, {Naoto T.}",
year = "2003",
month = "5",
doi = "10.1016/S1083-8791(03)00088-0",
language = "English (US)",
volume = "9",
pages = "330--340",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation

T2 - Implications for patient selection

AU - Montemurro, Filippo

AU - Randón, Gabriela

AU - Munsell, Mark

AU - Smith, Terry L.

AU - Donato, Michele L.

AU - Gajewski, James L.

AU - Rahman, Zia U.

AU - Buzdar, Aman U.

AU - Champlin, Richard E.

AU - Ueno, Naoto T.

PY - 2003/5

Y1 - 2003/5

N2 - The aim of this study was to study the effectiveness of the Swenerton score in assessing extent of disease as an independent prognostic and predictive factor in patients with metastatic breast cancer (MBC) who receive high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell transplant (AHSCT). Two-hundred thirty-two patients with MBC underwent HDCT. Extent of disease was assessed quantitatively using the Swenerton score. A retrospective analysis was performed using Cox proportional hazards regression and logistic regression models. One hundred three (44%) patients had a complete response (CR) after HDCT. Bone marrow as source of hematopoietic stem cells, hormone-receptor-negative status, and visceral involvement correlated with both worse overall survival (OS) and progression-free survival (PFS). Short disease-free interval, multiple sites of metastatic disease, and less than 50% reduction in the Swenerton Score during induction chemotherapy correlated with worse OS. Patients in CR at the time of HDCT had better PFS than patients in partial response, stable disease, or progressive disease. Fifty-six patients who underwent conversion to CR after HDCT had a similar median OS (not reached v 74 months; P = .51) and PFS duration (22 v 44 months; P = .15) as patients who received HDCT after a CR to standard-dose chemotherapy (SDCT). Conversion to CR was predicted by a ≥50% reduction in the Swenerton score during SDCT (odds ratio [OR] 3.32, P <.01) and soft-tissue disease (OR 4.08, P <.01). The presence of multiple metastatic sites predicted decreased probability of conversion to CR (OR 0.34, P <.01). The Swenerton score provides a thorough estimate of disease extent, and reduction of Swenerton score by SDCT is potentially useful for selecting the optimal candidates for HDCT trials who may achieve long-term disease control.

AB - The aim of this study was to study the effectiveness of the Swenerton score in assessing extent of disease as an independent prognostic and predictive factor in patients with metastatic breast cancer (MBC) who receive high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell transplant (AHSCT). Two-hundred thirty-two patients with MBC underwent HDCT. Extent of disease was assessed quantitatively using the Swenerton score. A retrospective analysis was performed using Cox proportional hazards regression and logistic regression models. One hundred three (44%) patients had a complete response (CR) after HDCT. Bone marrow as source of hematopoietic stem cells, hormone-receptor-negative status, and visceral involvement correlated with both worse overall survival (OS) and progression-free survival (PFS). Short disease-free interval, multiple sites of metastatic disease, and less than 50% reduction in the Swenerton Score during induction chemotherapy correlated with worse OS. Patients in CR at the time of HDCT had better PFS than patients in partial response, stable disease, or progressive disease. Fifty-six patients who underwent conversion to CR after HDCT had a similar median OS (not reached v 74 months; P = .51) and PFS duration (22 v 44 months; P = .15) as patients who received HDCT after a CR to standard-dose chemotherapy (SDCT). Conversion to CR was predicted by a ≥50% reduction in the Swenerton score during SDCT (odds ratio [OR] 3.32, P <.01) and soft-tissue disease (OR 4.08, P <.01). The presence of multiple metastatic sites predicted decreased probability of conversion to CR (OR 0.34, P <.01). The Swenerton score provides a thorough estimate of disease extent, and reduction of Swenerton score by SDCT is potentially useful for selecting the optimal candidates for HDCT trials who may achieve long-term disease control.

KW - Autologous transplantation

KW - Breast neoplasm

KW - High-dose chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=12144289539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144289539&partnerID=8YFLogxK

U2 - 10.1016/S1083-8791(03)00088-0

DO - 10.1016/S1083-8791(03)00088-0

M3 - Article

C2 - 12766883

AN - SCOPUS:12144289539

VL - 9

SP - 330

EP - 340

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 5

ER -